Comment on Novo Nordisk's Pricing Pressures Aren't Going Away

Novo Nordisk's Pricing Pressures Aren't Going Away

There wasn't anything in Novo Nordisk's (NYSE: NVO) second-quarter results to get too excited about, and it appears the company will continue to face pricing pressure for its diabetes drugs from payers next year as well.MetricQ2 2018Continue reading

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News